AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Interest Income

Income earned on cash, deposits, and investments held by the company.

AC Immune S.A.NASDAQ: ACIU

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of CHF 228K fell 66.8% year over year, behind the -58.3% change in trailing-twelve-month interest income. Sequentially, it fell 34.9% from the prior quarter. Over 3 fiscal years it compounded at +200.1% a year.

Context

  • Interest income amounted to 52.2% of revenue in FY2025, up 40.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -66.8% toward the trailing-twelve-month pace of -58.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 228K-34.9% QoQ
Last fiscal yearDec 2025
CHF 1.87M-41.6% YoY
LTMMar 2026
CHF 1.36M-58.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.8%——
1 year-41.6%——
3-year CAGR+200.1%——
5-year CAGR——
10-year CAGR——

Interest Income history

CHF · from the income statement

Latest · FY2025
1.87M CHF
Year-over-year change
-41.6%
4-year CAGR
-26.8%

Interest Income vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -58.3% is the 8th highest of 10, against a peer median of -40.4%.
  • Interest income amounts to 36.6% of revenue for ACIU, versus a peer median of 12.4%.
ACIU Competitors
Interest Income for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$11.41M USD-45.9%+22.9%36812.9%
AMRNAmarin Corporation plcLTM Mar 2026$10.41M USD-19.3%+56.7%4.8%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$8.5M USD-10.7%+121.3%—
CLLSCellectis S.A.LTM Mar 2026$8.47M USD-30.9%+103.9%12.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$6.34M USD-30.5%+286.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.91M USD-45.8%+12.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.84M USD-40.4%+46.2%367.5%
ACIUAC Immune S.A.LTM Mar 2026CHF 1.36M CHF-58.3%+200.1%36.6%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$944K USD-79.3%+28.9%—
SLNSilence Therapeutics plcLTM Mar 2026$0 USD—+148.8%0.0%
ANNXAnnexon, Inc.LTM Mar 2026-$1.14M USD-107.3%+38.6%—
Peer median (excluding ACIU) —-40.4%+51.4%12.4%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.